(MENAFN- Straits Research)
Animal Model Market Size & Growth Analysis
The global animal model market size was valued at USD 2.91 billion in 2025 and is projected to grow from USD 3.15 billion in 2026 to USD 5.99 billion by 2034, registering a CAGR of 8.36% during the forecast period from 2026 to 2034. North America dominated the animal model market with a market share of 41.8% in 2025.
Animal models are living animals used in biomedical research to study biological processes, diseases, drug efficacy, safety, and potential therapeutic approaches. Common models include mice, rats, rabbits, zebrafish, and other laboratory animals selected according to research requirements. Animal models help researchers understand disease mechanisms, evaluate experimental treatments, assess drug toxicity, and generate preclinical data before potential therapies advance to human clinical studies.
Animal Model Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 2.91 Billion
2026 Market Size: USD 3.15 Billion
2034 Projected Market Size: USD 5.99 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 8.36%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 41.8%
Fastest-Growing Region: Europe
Europe CAGR (2026–2034): 9.3%
Segment Insights
By Animal Type
Leading Segment: Mice
Market Share in 2025: 48.7%
By Application
Fastest-Growing Segment: Drug Discovery and Development
CAGR: 9.1% (2026–2034)
By End-User
Leading Segment: Pharma and Biotech Companies
Market Share in 2025: 58.6%
Download a Free Sample To learn more about this report,
Animal Model Market Trends
Growing Adoption of Genetically Engineered and Humanized Animal Models
The animal model market is increasingly shifting toward genetically engineered, disease-specific, and humanized models that can more closely replicate human disease biology. Advances in CRISPR-based gene editing are allowing researchers to create targeted mutations and complex disease phenotypes for oncology, immunology, neuroscience, metabolic disorders, and rare-disease research. These models are becoming increasingly valuable for target validation, drug screening, pharmacokinetic studies, and translational research because they can provide more disease-relevant biological responses than conventional models.
In March 2025, Alamar Biosciences introduced the NULISAseq Mouse Panel 120, a high-plex biomarker profiling solution designed to analyze protein expression in mouse models across inflammation, neurodegeneration, and immuno-oncology research. The launch demonstrates the industry's movement toward more sophisticated animal-model workflows combined with high-dimensional biomarker analysis.
Increasing Integration of AI and Human-Relevant Alternatives in Preclinical Research
Another important trend is the growing integration of artificial intelligence, computational modeling, organoids, and other human-relevant technologies alongside traditional animal models. Researchers and regulators are increasingly examining approaches that can improve translational accuracy, reduce study costs, and address ethical concerns associated with animal experimentation. Rather than immediately eliminating animal models, these technologies are increasingly being used as complementary tools to improve experimental design, predict toxicity, and identify which compounds should progress to in vivo testing.
In April 2025, the U.S. Food and Drug Administration announced a plan to reduce reliance on animal testing for monoclonal antibodies and other drugs by promoting human-relevant approaches, including AI-based computational models, organoids, and other laboratory methods. The initiative signals a significant shift toward integrating alternative technologies into preclinical development while reshaping how animal models are selected and used.
Animal Model Market Dynamics
Market Drivers
Growing Demand for Preclinical Disease Research
Animal models continue to play an important role in biomedical research because they allow researchers to study disease progression, biological mechanisms, drug responses, and treatment safety within living systems. Rodent, primate, zebrafish, and other models are selected according to the scientific question and can provide information that cannot always be obtained from isolated cells or computer models. This continues to support animal model market demand across pharmaceutical, biotechnology, academic, and research institutions. NIH also confirms that animal models remain important for many areas of biomedical research when scientifically appropriate.
In August 2026, the National Cancer Institute stated that animal models continue to be useful for answering important questions in cancer biology, while requiring researchers to justify their use when alternatives are inadequate.
Market Restraints
Increasing Preference for Human-Relevant Research Methods
The growing availability of organoids, tissue chips, computational models, and other human-based approaches is creating pressure to reduce animal use in certain research applications. These alternatives can potentially provide more human-relevant information for specific questions while reducing ethical and operational concerns associated with animal studies. This is influencing animal model market analysis as research institutions and pharmaceutical companies increasingly evaluate whether animal studies are scientifically necessary for individual applications. However, NIH notes that alternative approaches cannot currently reproduce every biological and behavioral aspect of human disease, meaning animal models remain relevant for many research questions.
In June 2026, NIH established the Office of Research Innovation, Validation, and Application to accelerate development and adoption of human-based research technologies, including 3D tissue models and computational approaches.
Market Opportunities
Development of More Predictive and Specialized Animal Models
Advances in genetic engineering, disease modeling, and precision research are creating opportunities for specialized animal models that better reproduce particular human diseases or biological characteristics. Genetically modified, humanized, immunodeficient, and patient-derived models can support more targeted studies in oncology, immunology, infectious diseases, and drug development. These developments are shaping animal model market trends toward models designed for specific research questions rather than generalized laboratory use. Combining animal models with human-based methods can also provide researchers with complementary evidence during preclinical development.
In March 2026, NIH launched more than USD 150 million in Complement-ARIE awards to develop and standardize human-based research methods, creating opportunities for researchers to combine or compare advanced alternatives with established animal models.
Market Challenges
Balancing Scientific Value With Animal Welfare and Regulatory Expectations
Animal-model providers and research institutions must balance the scientific value of animal studies with ethical responsibilities, welfare requirements, and growing regulatory interest in alternative methods. Researchers are expected to apply the principles of replacement, reduction, and refinement and use the minimum number of animals scientifically necessary. This remains a key consideration for the animal model market report because model selection increasingly depends on scientific relevance, reproducibility, translational value, and ethical justification. Regulatory expectations are also evolving as agencies establish pathways for evaluating non-animal methodologies alongside conventional preclinical approaches.
In March 2026, the FDA issued draft guidance outlining principles for validating new approach methodologies, including human biological relevance, technical characterization, and fit-for-purpose use in drug development.
Animal Model Market Segmentation Analysis
By Animal Type
Mice Segment Dominated the Market with 48.7% Share in 2025
The mice segment dominated the global animal model market with a 48.7% share in 2025, driven by their genetic similarity to humans, well-established research protocols, relatively short reproductive cycles, and suitability for developing disease models. Mice are extensively used in biomedical research, preclinical studies, genetics, immunology, oncology, and drug development, supporting their widespread adoption across research institutions and pharmaceutical organizations.
The rat segment continues to play an important role in pharmacology, toxicology, neuroscience, and behavioral research because of its physiological characteristics and established use in laboratory studies. The guinea pig segment is supported by applications in immunology, infectious disease research, respiratory studies, and vaccine development.
The rabbit segment is gaining demand in areas such as antibody production, ophthalmology, cardiovascular research, and medical device evaluation. Other animal models contribute to market growth through specialized applications where alternative species are required for specific physiological, genetic, or disease-related research needs.
Request Customization to receive a tailored report.
By Application
Drug Discovery and Development Segment Dominated the Market with 55.9% Share in 2025
The drug discovery and development segment dominated the global animal model market with a 55.9% share in 2025, driven by the extensive use of animal models for evaluating drug efficacy, safety, pharmacokinetics, and potential toxicity before clinical trials. Increasing pharmaceutical R&D activities and the development of therapies for complex diseases continue to support demand for reliable preclinical animal models.
The basic research segment is expanding through increasing use of animal models in genetics, physiology, neuroscience, immunology, and disease-mechanism studies. Researchers rely on established animal models to understand biological processes and investigate potential therapeutic targets. Other applications contribute to market demand through specialized research, educational activities, and testing requirements across biomedical and life science fields.
By End-User
Pharma and Biotech Companies Segment Dominated the Market with 58.6% Share in 2025
The pharma and biotech companies segment dominated the global animal model market with a 58.6% share in 2025, supported by extensive preclinical research activities required for drug discovery, development, safety assessment, and therapeutic validation. Increasing investment in novel medicines and biologic therapies is encouraging pharmaceutical and biotechnology companies to utilize animal models throughout the development process.
The academic research institutes segment is expanding through increasing biomedical research, disease investigation, genetics studies, and translational research activities. Academic institutions use animal models to investigate fundamental biological mechanisms and evaluate potential therapeutic approaches. Other end-users contribute to demand through contract research, specialized testing, government-supported research, and other life science activities.
Speak to an Analyst to discuss market opportunities.
Animal Model Market Regional Outlook
North America Animal Model Market Analysis
The North American animal model market accounted for 41.8% of the global market, reaching USD 1.22 billion in 2025. The region holds the largest market share, supported by extensive biomedical research activities, established pharmaceutical and biotechnology industries, strong research infrastructure, and continued demand for preclinical testing and disease-model development.
United States Animal Model Market Insights
The United States represents a major market in North America. Its large pharmaceutical and biotechnology sector, extensive academic research infrastructure, and strong focus on drug discovery and preclinical research continue to support demand for animal models.
Canada Animal Model Market Insights
Canada's established biomedical research ecosystem, pharmaceutical industry, and academic research institutions continue to support the development and use of animal models in preclinical studies.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Animal Model Market Analysis
The European animal model market accounted for 28.6% of the global market, reaching USD 0.83 billion in 2025, and is projected to grow at the fastest CAGR of 9.3% during the forecast period. Growth is supported by increasing pharmaceutical research, biotechnology development, preclinical testing, and investments in advanced disease and genetic models.
Germany Animal Model Market Insights
Germany represents a major European market. Its strong pharmaceutical and biotechnology industries, research institutions, and expanding preclinical research activities continue to support animal model adoption.
United Kingdom Animal Model Market Insights
The United Kingdom's established life sciences sector, academic research base, and pharmaceutical research activities continue to drive demand for animal models in biomedical and preclinical research.
Asia Pacific Animal Model Market Analysis
The Asia Pacific animal model market accounted for 21.4% of the global market, reaching USD 0.62 billion in 2025, and is expected to grow at a CAGR of 8.9% during the forecast period. Expanding pharmaceutical and biotechnology industries, increasing research investments, and growing preclinical drug development activities continue to support regional market growth.
China Animal Model Market Insights
China represents a major market within the Asia Pacific. Its expanding pharmaceutical and biotechnology sectors, increasing biomedical research investments, and growing drug discovery activities continue to support animal model market development.
Japan Animal Model Market Insights
Japan's advanced pharmaceutical industry, established biomedical research infrastructure, and strong focus on life sciences research continue to support demand for animal models.
India Animal Model Market Insights
India's expanding pharmaceutical and biotechnology industries, increasing research and development activities, and growing preclinical testing requirements continue to create opportunities for animal model market growth.
Latin America Animal Model Market Analysis
Latin America's animal model market accounted for 4.7% of the global market, reaching USD 0.14 billion in 2025, and is projected to grow at a CAGR of 7.5% during the forecast period. Expansion of pharmaceutical research, biotechnology activities, and biomedical research infrastructure continues to support regional demand.
Brazil Animal Model Market Insights
Brazil represents a major regional market. Its growing pharmaceutical sector, biomedical research capabilities, and expanding academic research activities continue to support animal model adoption.
Middle East & Africa Animal Model Market Analysis
The Middle East & Africa animal model market accounted for 3.5% of the global market, reaching USD 0.10 billion in 2025, and is anticipated to grow at a CAGR of 7.1% during the forecast period. Increasing healthcare and life sciences investments, research infrastructure development, and growing pharmaceutical activities continue to support regional market expansion.
UAE Animal Model Market Insights
The UAE's investments in healthcare, biotechnology, and scientific research infrastructure continue to create opportunities for animal model market development.
Saudi Arabia Animal Model Market Insights
Saudi Arabia's expanding healthcare and life sciences ecosystem, research investments, and pharmaceutical development activities continue to support demand for animal models in biomedical research.
Animal Model Market Competitive Landscape
The global animal model market is highly competitive, with leading contract research organizations, biotechnology companies, laboratory animal suppliers, and preclinical research providers competing through genetically engineered models, transgenic animals, knockout models, humanized models, disease-specific models, and customized research services. The major players in the market include Charles River Laboratories, The Jackson Laboratory, Genoway S.A., Taconic Biosciences, Inc., Janvier Labs, Harbour BioMed, Crown Bioscience, Envigo RMS, LLC, Inotiv, BIOCYTOGEN, BioSpherix, Ltd., Ozgene Pty, Trans Genic Inc., Hera BioLabs, and B&K Universal, among others.
Industry participants are focusing on developing more predictive and disease-relevant animal models to support drug discovery, toxicology, immunology, oncology, and preclinical research. Companies are investing in genetically engineered models, humanized immune-system models, precision breeding, CRISPR-based gene editing, cryopreservation, model characterization, and customized research services. Growing pharmaceutical and biotechnology R&D expenditure, increasing drug development activity, demand for translational research models, and rising adoption of genetically modified and humanized animals are encouraging companies to expand their model portfolios and research capabilities.
Charles River Laboratories: An Emerging Market Leader
Charles River Laboratories is one of the leading companies in the global animal model market, providing laboratory animal models, genetically engineered models, preclinical research services, and specialized discovery and development solutions for pharmaceutical and biotechnology companies. Its portfolio supports research across oncology, immunology, infectious diseases, metabolic disorders, and other therapeutic areas.
In 2026, Charles River Laboratories continued strengthening its preclinical research and animal model portfolio, with emphasis on genetically engineered models, specialized disease models, research services, and technologies designed to improve the translation of preclinical findings into clinical development. The company continued investing in integrated research capabilities and expanding solutions that support pharmaceutical and biotechnology customers across the drug discovery lifecycle. These initiatives reinforce Charles River Laboratories' competitive position in the global animal model market.
List of Key and Emerging Players in Animal Model Market
Charles River Laboratories
The Jackson Laboratory
Genoway S.A
Taconic Biosciences, Inc.
Janvier Labs
Harbour BioMed
Crown Bioscience
Envigo RMS, LLC
Inotiv
BIOCYTOGEN
BioSpherix, Ltd.
Ozgene Pty
Transgenic Inc.
Hera Biolabs
B&K Universal
Key Industry Developments
June 2026: Charles River Laboratories expanded its preclinical research capabilities by advancing animal model platforms, genetic models, and translational research services. The company focused on supporting pharmaceutical and biotechnology companies in drug discovery and development programs.
May 2026: The Jackson Laboratory expanded its research model portfolio by advancing genetically engineered mouse models and precision medicine research solutions. The initiatives focused on improving disease modeling and biomedical research applications.
April 2026: Envigo (Inotiv) expanded its preclinical research capabilities by advancing laboratory animal models, research services, and study support solutions. The company focused on supporting pharmaceutical development and safety testing programs.
January 2026: Taconic Biosciences expanded its genetically engineered animal model portfolio by advancing customized research models and breeding technologies. The company focused on supporting oncology, immunology, and drug discovery research.
Report Scope
Comments
No comment